HIT: treatment easier, prevention harder.

In this issue of Blood, Krauel and colleagues identify two potential off-label treatments(rivaroxaban, dabigatran) for heparin-induced thrombocytopenia (HIT),and also outline aHIT prevention strategy through disrupting PF4/heparin complexes with low-sulfated heparin; the former approach will be easy to implement, the latter much harder—but potentially more worthwhile